Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy

Antwerp, Belgium - 27 August, 2025 - Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1.0 million grant from Flanders Innovation & Entrepreneurship (VLAIO).

This two-year grant will accelerate the development of Spica’s lead anti-CD163 depleting monoclonal antibody program in oncology, propelling it toward early Investigational New Drug (IND)-enabling studies.

James Rush, CEO of Spica Therapeutics, stated:

“We are honored that VLAIO recognizes the potential of our innovative approach to selectively target disease-relevant macrophage subsets. This funding will significantly strengthen our efforts to advance our lead anti-CD163 monoclonal antibody into IND-enabling studies. It also underscores Spica’s deep integration within Flanders’ world-class innovation ecosystem—an environment that continues to fuel our global mission.”

As part of the VLAIO-supported initiative, Spica will collaborate with leading academic partners in Flanders:

  • The Molecular Imaging and Therapy (MITH) research group at Vrije Universiteit Brussel (VUB), led by Prof. Nick Devoogdt, renowned for his translational work in radiotracer development for non-invasive imaging of cancer and immune cells.
  • The Myeloid Cell Immunology Lab at VIB and the Brussels Center for Immunology (BCIM) at VUB, under the leadership of Prof. Jo Van Ginderachter, internationally recognized for his research on the role of myeloid cells - particularly macrophages - in cancer and infectious diseases.

Hilde Revets, Director of Non-Clinical Operations and Anders Etzerodt, CSO at Spica Therapeutics, added:

“These collaborations will be instrumental in deepening our understanding of macrophage biology and accelerating the translation of our therapeutic candidates. We’re excited to work alongside such esteemed partners to bring new hope to patients.”

 

About Spica Therapeutics

Spica Therapeutics NV is a cutting-edge biotechnology company committed to transforming macrophage biology into breakthrough therapies for patients across a range of therapeutic areas. Founded on pioneering research from the University of Aarhus, Southern Denmark University, and INSERM, Spica is headquartered in Antwerp, Belgium, with an additional site in Denmark.

Leveraging its proprietary functional macrophage fingerprinting technology, Spica is uniquely positioned to identify and selectively target disease-relevant macrophage subsets. This platform enables the development of novel therapies aimed at addressing significant unmet medical needs in oncology, fibroinflammatory, and autoimmune diseases.

Spica is currently advancing two lead programs with the goal of delivering life-changing treatments to patients worldwide. The company is backed by prominent investors, including Bioqube Ventures, Flanders Future TechFund (managed by PMV), and QBIC.

About VUB

Vrije Universiteit Brussel (VUB) is an internationally oriented university in Brussels, the heart of Europe. By providing excellent research and education on a human scale, VUB wants to make an active and committed contribution to a better society.

About VIB

VIB is a leading life sciences research institute based in Belgium, operating in close partnership with the Flemish universities and renowned for its work in medical sciences, plant biology, microbiology, artificial intelligence and biotechnology. VIB's mission is to push the boundaries of scientific discovery, transform it into disruptive biotech innovations and support the growth of the life sciences ecosystem in Flanders (Belgium).

Media Contact

info@spicatherapeutics.com

 

Share

Latest stories

Researchers discover clues for Alzheimer’s disease in hibernation

Researchers discover clues for Alzheimer’s disease in hibernation

Leuven, 12 November 2026 – Researchers at VIB and KU Leuven have discovered that hibernation triggers changes in brain cells that partially resemble those in Alzheimer’s disease. Studying golden hamsters, the team identified changes in gene expression across the hibernation cycle, which resemble those associated with the accumulation of amyloid plaques in Alzheimer’s. The findings, published in Science Advances, suggest that some early cellular changes associated with Alzheimer’s may also occur as part of a natural adaptive response, offering new ways to study the disease for therapy development.

press.vib.be

An inside look at a molecular switch that triggers inflammation

An inside look at a molecular switch that triggers inflammation

Ghent, 9 November 2026 – Researchers at VIB and Ghent University have uncovered how an important driver of inflammation is activated at the molecular level. Their findings, published in Science Immunology, also explain how a medicine used to treat a severe form of psoriasis blocks this inflammatory signal.

press.vib.be

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Leuven, 4 November 2026 – Researchers at VIB and KU Leuven have uncovered how mutations in the ASPM gene disrupt the development of neural stem cells that help the human brain grow. This disruption explains how these mutations cause microcephaly, a condition characterized by an abnormally small brain and head, often accompanied by intellectual disability. The discovery, published in Developmental Cell, also sheds light on how differences in brain development can make humans more susceptible to certain genetic conditions than other mammals.

press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be